Daunorubicin/cytarabine
Daunorubicin/Cytarabine
Daunorubicin/Cytarabine, pronounced as (daw-noe-ROO-bi-sin/sye-TARE-a-been), is a combination medication used in the treatment of acute myeloid leukemia (AML).
Etymology
The name Daunorubicin is derived from the bacterium Streptomyces peucetius from which it was first isolated, while Cytarabine is a synthetic compound derived from cytosine, a nucleoside of DNA.
Usage
Daunorubicin/Cytarabine is used for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes.
Mechanism of Action
Daunorubicin has antimitotic and cytotoxic activity, while Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only in the S phase of cell division. When combined, they work synergistically to inhibit the progression of the disease.
Side Effects
Common side effects of Daunorubicin/Cytarabine include fever, nausea, muscle pain, and fatigue. More serious side effects may include cardiotoxicity, myelosuppression, and hepatotoxicity.
Related Terms
- Chemotherapy
- Antineoplastic Agents
- Acute Myeloid Leukemia
- Myelodysplasia
- Cardiotoxicity
- Myelosuppression
- Hepatotoxicity
External links
- Medical encyclopedia article on Daunorubicin/cytarabine
- Wikipedia's article - Daunorubicin/cytarabine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski